close

Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated. Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	7.67
Volume	224639
Volume Avg	152747
52 Week High	7.35
52 Week Low	3.61
PE	N/A
PE (group average)	39
EPS Year	-0.16
EPS change Q/Q	-1000%
EPS change Q/Q Yr ago	-1000%
EPS change Q/Q next Q est	-100%
EPS change Y/Y	-23.68%
REV change Q/Q	68.75%
REV change Q/Q Yr ago	27.36%
EPS next Q est	0.00
EPS next Y est	0.51
Divident Annual	0.00
Dividend Yield	0%